These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

736 related items for PubMed ID: 12543790

  • 1. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli DH, Boschelli F.
    Cancer Res; 2003 Jan 15; 63(2):375-81. PubMed ID: 12543790
    [Abstract] [Full Text] [Related]

  • 2. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE.
    Oncogene; 2002 Nov 21; 21(53):8075-88. PubMed ID: 12444544
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
    Huang M, Dorsey JF, Epling-Burnette PK, Nimmanapalli R, Landowski TH, Mora LB, Niu G, Sinibaldi D, Bai F, Kraker A, Yu H, Moscinski L, Wei S, Djeu J, Dalton WS, Bhalla K, Loughran TP, Wu J, Jove R.
    Oncogene; 2002 Dec 12; 21(57):8804-16. PubMed ID: 12483533
    [Abstract] [Full Text] [Related]

  • 4. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K.
    Cancer Res; 2002 Oct 15; 62(20):5761-9. PubMed ID: 12384536
    [Abstract] [Full Text] [Related]

  • 5. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606.
    Mancini M, Brusa G, Zuffa E, Corrado P, Martinelli G, Grafone T, Barbieri E, Santucci MA.
    Leuk Res; 2007 Jul 15; 31(7):979-87. PubMed ID: 17129604
    [Abstract] [Full Text] [Related]

  • 6. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.
    Golas JM, Lucas J, Etienne C, Golas J, Discafani C, Sridharan L, Boghaert E, Arndt K, Ye F, Boschelli DH, Li F, Titsch C, Huselton C, Chaudhary I, Boschelli F.
    Cancer Res; 2005 Jun 15; 65(12):5358-64. PubMed ID: 15958584
    [Abstract] [Full Text] [Related]

  • 7. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
    Keller G, Schafhausen P, Brummendorf TH.
    Expert Rev Hematol; 2009 Oct 15; 2(5):489-97. PubMed ID: 21083014
    [Abstract] [Full Text] [Related]

  • 8. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 9. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
    Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G.
    Leukemia; 2009 Mar 01; 23(3):477-85. PubMed ID: 19039322
    [Abstract] [Full Text] [Related]

  • 10. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
    Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D, Hallek M, Van Etten RA, Li S.
    Nat Genet; 2004 May 01; 36(5):453-61. PubMed ID: 15098032
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.
    Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551
    [Abstract] [Full Text] [Related]

  • 12. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
    Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA.
    Cancer Res; 2007 Feb 15; 67(4):1580-8. PubMed ID: 17308097
    [Abstract] [Full Text] [Related]

  • 13. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
    Konig H, Holyoake TL, Bhatia R.
    Blood; 2008 Feb 15; 111(4):2329-38. PubMed ID: 18056843
    [Abstract] [Full Text] [Related]

  • 14. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
    Kindler T, Breitenbuecher F, Kasper S, Stevens T, Carius B, Gschaidmeier H, Huber C, Fischer T.
    Leukemia; 2003 Jun 15; 17(6):999-1009. PubMed ID: 12764361
    [Abstract] [Full Text] [Related]

  • 15. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
    Gutiérrez-Castellanos S, Cruz M, Rabelo L, Godínez R, Reyes-Maldonado E, Riebeling-Navarro C.
    Eur J Haematol; 2004 Apr 15; 72(4):231-8. PubMed ID: 15089759
    [Abstract] [Full Text] [Related]

  • 16. Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia.
    Boschelli F, Arndt K, Gambacorti-Passerini C.
    Eur J Cancer; 2010 Jul 15; 46(10):1781-9. PubMed ID: 20399641
    [Abstract] [Full Text] [Related]

  • 17. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
    Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, Ahmed S, Redaelli S, Piazza R, Magistroni V, Andreoni F, Scapozza L, Formelli F, Gambacorti-Passerini C.
    Cancer Res; 2006 Dec 01; 66(23):11314-22. PubMed ID: 17114238
    [Abstract] [Full Text] [Related]

  • 19. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
    Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM.
    Clin Cancer Res; 2003 Apr 01; 9(4):1267-73. PubMed ID: 12684394
    [Abstract] [Full Text] [Related]

  • 20. Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl.
    Mc Gee MM, Campiani G, Ramunno A, Fattorusso C, Nacci V, Lawler M, Williams DC, Zisterer DM.
    J Pharmacol Exp Ther; 2001 Jan 01; 296(1):31-40. PubMed ID: 11123359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.